Across TCGA pan-cancer cohorts, CDRT15P2 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of CDRT15P2’s most consistent transcriptional readouts.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where CDRT15P2 RNA is repressed in tumor relative to normal tissue. In most cancer types CDRT15P2 is over-expressed in tumor, although a few such as PRAD and KIRC show the opposite, repressed pattern.

PRAD, KIRC, and KIRP are the cancer types where CDRT15P2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CDRT15P2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PRAD	All	All	−0.052	.047	2	view →
KIRC	All	All	−0.030	.005	2	view →
KIRP	Male	All	−0.044	.022	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: CDRT15P2 RNA expression & survival · all CDRT15P2 data types